Latest News and Press Releases

BRIDGEWATER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...

First quarter 2019 total revenue of $57.1 million; net loss of $6.2 million Positive topline results from second Phase III clinical trials of RVL-1201 for ptosis or droopy eyelid BRIDGEWATER, N.J.,...

- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety - - Long-term Phase III Study 203 Provides Additional Evidence of Safety - - Company to Host...

BRIDGEWATER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the...

Reported fourth quarter and full year 2018 total revenue of $65.7 million and $263.7 million, respectively Completed and reported preliminary topline results from second Phase III study of arbaclofen...

BRIDGEWATER, N.J., March 21, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...

BRIDGEWATER, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...

BRIDGEWATER, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that...

BRIDGEWATER, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced...

BRIDGEWATER, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the...